Your session is about to expire
← Back to Search
Hormone Therapy
400 µg once-weekly by subcutaneous injection for Hypoparathyroidism
Phase 2
Waitlist Available
Research Sponsored by MBX Biosciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
1. Must have completed the Week 12 Visit in MBX-2H1002 Study.
2. Is an adult ≥18 years of age at the time of the Screening visit of this extension study.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 104 weeks
Awards & highlights
Summary
The purpose of this study is to evaluate the long-term safety and tolerability of MBX 2109 in patients with hypoparathyroidism who completed the 12-week treatment period in the Phase 2 study, MBX-2H1002.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 104 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~104 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
To evaluate the long-term safety and tolerability of weekly MBX 2109 in patients with hypoparathyroidism.
Trial Design
2Treatment groups
Experimental Treatment
Group I: 400 µg once-weekly by subcutaneous injectionExperimental Treatment1 Intervention
Group II: 200-1600 µg once-weekly by subcutaneous injectionExperimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
MBX BiosciencesLead Sponsor
3 Previous Clinical Trials
208 Total Patients Enrolled
1 Trials studying Hypoparathyroidism
48 Patients Enrolled for Hypoparathyroidism
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger